Find a Research Expert

Experts
 Menu

Alex J Eustace

Institution

Dublin City University

Contact

Subjects

Biochemistry

Medicine & Nursing

Microbiology

Details
Publications 27
As first author 6
As last author 5
Unique topics 217
Collaborations 72
Sources 6
Are you Alex J Eustace? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2011
2010
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2011
2010
Earlier

2019

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
2018

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
2018

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
2017

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
2016

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
2016

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
2015

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
2015

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
2015

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
2014

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
2014

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
2014

Predictive biomarkers for dasatinib treatment in melanoma
2013

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.
2013

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
2011

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines
2011

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
2010

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
2010

Artificial neural networks for classification in metabolomic studies of whole cells using 1H nuclear magnetic resonance.
2010

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
2010

Prospects for non-immunological molecular therapeutics in melanoma.
2008

Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts.
2008

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
2007

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.

These arethe6 unique sources for Alex J Eustace's 27 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 16
Ireland -> Dublin City University -> PubMed 15
Ireland -> Maynooth University 1
Ireland -> Royal College of Surgeons in Ireland 9
Ireland -> Royal College of Surgeons in Ireland -> PubMed 6
Ireland -> Trinity College Dublin 3

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.